Anzeige
Mehr »
Sonntag, 08.06.2025 - Börsentäglich über 12.000 News
5-Dollar-Kupfer. KI-Infrastruktur. Energiewende. Vizsla Copper hat die Pfunde im Boden, die jetzt zählen.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFQL | ISIN: SE0008015259 | Ticker-Symbol: 9IB
Stuttgart
06.06.25 | 10:50
5,130 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INFANT BACTERIAL THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
INFANT BACTERIAL THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur INFANT BACTERIAL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.05.Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Interim report January 1 - March 31, 202565Message from CEO The US Food and Drug Administration (FDA) has granted IBP-9414 "Breakthrough Therapy Designation." This means that the FDA and IBT will work together to bring the new drug to market...
► Artikel lesen
28.03.Infant Bacterial Therapeutics: IBT is granted Breakthrough Therapy Designation for its Drug Candidate48The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for IBP-9414's potential to reduce gastrointestinal-related mortality. A breakthrough designation is intended...
► Artikel lesen
INFANT BACTERIAL THERAPEUTICS Aktie jetzt für 0€ handeln
13.02.Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Year-end report January 1 - December 31, 202452Message from the CEO The scientific literature suggests that benign bacteria of the type found in IBT's drug product IBP-9414 can positively affect the health of premature infants. In 2024, we received...
► Artikel lesen
20.12.24Infant Bacterial Therapeutics Continues Development of Drug Candidate IBP-9414459IBT received results in August from the largest ever randomized clinical trial in premature infants. During the fall, IBT has continued to review the phase 3 results. Parts of the results have previously...
► Artikel lesen
14.11.24Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Interim report January 1 - September 30, 2024180Message from the CEO This quarter, IBT completed the global Phase 3 clinical trial "The Connection Study" for the drug candidate IBP-9414. On July 8, we reported that the last patient was treated. On...
► Artikel lesen
28.08.24Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ), Interim report January 1 - June 30, 2024161Message from the CEO IBT has announced the crucial results from the global clinical phase 3 study "The Connection Study" for our drug project IBP-9414 are expected in Q3 2024. On the 8th of July, we...
► Artikel lesen
6 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1